Drug Trial Radar · NCT05438043
A Study of Daratumumab
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
214
Actual
Start
Dec 15, 2022
Primary completion
Jan 31, 2029
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Conditions
- Multiple Myeloma
Interventions
DaratumumabDrug
Daratumumab will be administered either intravenously or subcutaneously.
CarfilzomibDrug
Carfilzomib will be administered intravenously.
DexamethasoneDrug
Dexamethasone will be administered either orally or intravenously.
LenalidomideDrug
Lenalidomide will be administered orally.
PomalidomideDrug
Pomalidomide will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Serious Adverse Events (SAEs)Time frame: 3 years 7 months
- Number of Participants with AEs of Special Interest (AESI)Time frame: 3 years 7 months
- Number of Participants with Pregnancies or Partner PregnanciesTime frame: 3 years 7 months
- Number of Participants with Abnormal Pregnancies as SAETime frame: 3 years 7 months
Locations
92 sites in 17 countries. Site status is shown where the registry gives one.
University of Miami Sylvester Cancer Center
Miami, Florida
Emory University
Atlanta, Georgia
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Barnes-jewish Hospital
St Louis, Missouri
Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Baylor University Medical Center
Dallas, Texas
ZAS Cadix
Antwerp, Belgium
Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
Campinas, Brazil
Liga Norte Riograndense Contra O Cancer
Natal, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
Porto Alegre, Brazil
Ministerio da Saude Instituto Nacional do Cancer
Rio de Janeiro, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
São Paulo, Brazil
Clinica Medica Sao Germano LTDA
São Paulo, Brazil
Peking Union Medical College Hospital
Beijing, China
Beijing Chaoyang Hospital
Beijing, China
Peking University First Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
West China Hospital Si Chuan University
Chengdu, China
Fujian Medical University
Fuzhou, China
Guangdong General Hospital
Guangzhou, China
Nanfang Hospital
Guangzhou, China
First Affiliated Hospital Medical School of Zhejiang University
Hangzhou, China
First affiliated Hospital of Zhejiang University
Hangzhou, China
Shanghai Changzheng Hospital
Shanghai, China
Ruijin Hospital Shanghai Jiao Tong University
Shanghai, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Tianjin cancer hospital
Tianjin, China
Institute of Hematology and Blood Diseases Hospital
Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Henan Cancer Hospital
Zhengzhou, China
Fakultni nemocnice Brno
Brno, Czechia
Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni (Main)
Pilsen, Czechia
Všeobecná fakultní nemocnice v
Prague, Czechia
Aarhus University Hospital
Aarhus N, Denmark
Centre Hospitalier Universitaire (CHU) de Caen
Caen, France
CHU Nantes
Nantes, France
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.